[go: up one dir, main page]

ZA200600176B - Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases - Google Patents

Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases

Info

Publication number
ZA200600176B
ZA200600176B ZA200600176A ZA200600176A ZA200600176B ZA 200600176 B ZA200600176 B ZA 200600176B ZA 200600176 A ZA200600176 A ZA 200600176A ZA 200600176 A ZA200600176 A ZA 200600176A ZA 200600176 B ZA200600176 B ZA 200600176B
Authority
ZA
South Africa
Prior art keywords
treatment
combination
chemotherapeutic agents
kinase inhibitors
proliferative diseases
Prior art date
Application number
ZA200600176A
Other languages
English (en)
Inventor
Francis Y F Lee
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ZA200600176B publication Critical patent/ZA200600176B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200600176A 2003-07-09 2006-01-06 Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases ZA200600176B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48577903P 2003-07-09 2003-07-09

Publications (1)

Publication Number Publication Date
ZA200600176B true ZA200600176B (en) 2010-06-30

Family

ID=34135068

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200600176A ZA200600176B (en) 2003-07-09 2006-01-06 Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases

Country Status (20)

Country Link
US (2) US20050009891A1 (no)
EP (1) EP1643996A4 (no)
JP (1) JP2007528849A (no)
KR (1) KR20060032627A (no)
CN (1) CN1849119A (no)
AU (1) AU2004263095B2 (no)
BR (1) BRPI0411864A (no)
CA (1) CA2531675A1 (no)
GE (1) GEP20094677B (no)
IL (1) IL173008A0 (no)
IS (1) IS8221A (no)
MX (1) MXPA06000191A (no)
NO (1) NO20060392L (no)
NZ (1) NZ544587A (no)
RS (1) RS20060011A (no)
RU (1) RU2006103858A (no)
TW (1) TW200505443A (no)
UA (1) UA83850C2 (no)
WO (1) WO2005013983A1 (no)
ZA (1) ZA200600176B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID30460A (id) 1999-04-15 2001-12-06 Bristol Myers Squibb Co Inhibitor-inhibitor protein siklik tirosin kinase
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
MXPA06012130A (es) * 2004-04-20 2007-01-31 Transtech Pharma Inc Derivados de tiazol y pirimidina substituidos como moduladores del receptor de melanocortina.
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
PE20061394A1 (es) * 2005-03-15 2006-12-15 Bristol Myers Squibb Co Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
WO2006135790A1 (en) * 2005-06-09 2006-12-21 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant kit protein
EP1937270A1 (en) * 2005-09-21 2008-07-02 Brystol-Myers Squibb Company Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
US20070093499A1 (en) * 2005-10-20 2007-04-26 Bristol-Myers Squibb Company Use of dasatinib for the treatment of bone metastasis
US20090099197A1 (en) * 2005-11-15 2009-04-16 Bristol-Myers Squibb Company Methods of Identifying and Treating Individuals Exhibiting MDR-1 Overexpression With Protein Tyrosine Kinase Inhibitors and Combinations Thereof
WO2007109527A1 (en) * 2006-03-17 2007-09-27 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant bcr/abl kinase polypeptides
WO2008076883A2 (en) * 2006-12-15 2008-06-26 Abraxis Bioscience, Inc. Triazine derivatives and their therapeutical applications
GB0625691D0 (en) * 2006-12-22 2007-01-31 Astrazeneca Ab Combination product
CN101265275B (zh) * 2007-02-16 2012-09-05 中国医学科学院药物研究所 4-{6-[5-(2-氯-6-甲基苯胺甲酰基)-噻唑-2-氨基]-2-甲基嘧啶-4}-哌嗪-1-磷酸二乙酯
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
JP2012501334A (ja) * 2008-08-29 2012-01-19 トランス テック ファーマ，インコーポレイテッド 置換アミノチアゾール誘導体、医薬組成物、および使用の方法
CN102822200A (zh) * 2009-07-20 2012-12-12 百时美施贵宝公司 对增殖性疾病进行协同性治疗的抗ctla-4抗体与各种治疗方案的组合
BR112014032346A2 (pt) 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
TWI770624B (zh) 2018-06-15 2022-07-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051910A (en) * 1989-10-16 1991-09-24 Honeywell Inc. Wind forecast error compensation for 4-D guidance in a aircraft flight management system
US5121325A (en) * 1990-04-04 1992-06-09 Smiths Industries Aerospace & Defense Systems, Inc. Required time of arrival (RTA) control system
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
ID30460A (id) * 1999-04-15 2001-12-06 Bristol Myers Squibb Co Inhibitor-inhibitor protein siklik tirosin kinase
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6507782B1 (en) * 2001-05-14 2003-01-14 Honeywell International Inc. Aircraft control system for reaching a waypoint at a required time of arrival
CA2810339A1 (en) 2001-08-10 2003-02-20 Novartis Ag Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
US20040209930A1 (en) * 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
US20050215795A1 (en) * 2004-02-06 2005-09-29 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US7652146B2 (en) * 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors

Also Published As

Publication number Publication date
US7622472B2 (en) 2009-11-24
US20080153842A1 (en) 2008-06-26
RS20060011A (sr) 2007-12-31
CN1849119A (zh) 2006-10-18
JP2007528849A (ja) 2007-10-18
AU2004263095A1 (en) 2005-02-17
CA2531675A1 (en) 2005-02-17
AU2004263095B2 (en) 2009-10-29
WO2005013983A1 (en) 2005-02-17
IS8221A (is) 2006-01-06
MXPA06000191A (es) 2006-04-11
TW200505443A (en) 2005-02-16
GEP20094677B (en) 2009-05-10
EP1643996A1 (en) 2006-04-12
US20050009891A1 (en) 2005-01-13
RU2006103858A (ru) 2006-06-27
IL173008A0 (en) 2006-06-11
KR20060032627A (ko) 2006-04-17
NZ544587A (en) 2009-07-31
EP1643996A4 (en) 2009-06-03
BRPI0411864A (pt) 2006-08-08
NO20060392L (no) 2006-02-03
UA83850C2 (ru) 2008-08-26

Similar Documents

Publication Publication Date Title
ZA200600176B (en) Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
IL197933A0 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
EP1664051A4 (en) PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USING SAME FOR TREATING PROLIFERATION DISORDERS
ZA200700223B (en) Quinazolin-4-yl-piperidine and cinnolin-4-yl-peperidine derivatives as PDE10 inhibitors for the treatment of CNS disorders
AU2003223380A8 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
IL176233A0 (en) Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors
IL178860A (en) Certain chemical entities, preparations and processes
PL373912A1 (en) Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
SI1627639T1 (sl) Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
IL180737A0 (en) Arylsulphonylstilbene derivatives for treatment of insomnia and related conditions
AU2003243561A1 (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
PT1487828E (pt) Derivados de morfolinil-ureia para utilização no tratamento de doenças inflamatórias
EP1812432A4 (en) COMBINATION OF AN SRC KINASE INHIBITOR AND A BCR ABL INHIBITOR FOR THE TREATMENT OF PROLIFERATIVE DISEASES
GB0321384D0 (en) Pteridine derivatives for the treatment of septic shock and TNF-alpha- related diseases
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
PL377933A1 (pl) Formulacja i sposoby leczenia trombocytemii
IL172018A0 (en) Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases
PL369736A1 (en) New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
GB2410744B (en) Kinase inhibitors for the treatment of disease
ZA200704971B (en) Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
ZA200606065B (en) Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies
HK1083687A (en) Combination of src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
SI1680405T1 (sl) Bengamidni derivati in njihova uporaba za zdravljenje rakavih bolezni